Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Director operating in the Pharmaceutical space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Robert Nelsen
Co-Founder & Managing Director of ARCH Venture Partners
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation. Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
Follow Robert Nelsen:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Keith Crandell
Founder and Managing Director of ARCH Venture Partners
Keith L. Crandell is the Co – Founder & Managing Director, ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. Mr. Crandell has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp. (acquired by Carl Zeiss SMT), Eichrom Industries (acquired by Gary Comer, Inc.), Nanophase Technologies (NANX), and Illinois Superconductor. He was also responsible for ARCH’s investment in New Era of Networks (NEON, acquired by Sybase-SY), Apropos Technology (APRS, acquired by Syntellect-ESL), Teach.com (acquired by Intellinex), CelebrateExpress (BDAY, acquired by Liberty Media-LINTA), Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Adesto Technologies, Ciespace, Boreal Genomics, and Crystal IS (acquired by Asahi Kasei-AHKSY), among others. He is a Director of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, Ciespace. Mr. Crandell also serves as a Director of the Illinois Venture Capital Association. Prior to the founding of ARCH, Mr. Crandell was with the specialty chemical and polymer company, Hercules, Inc. He holds an M.B.A. from The University of Chicago. An M.S. in Chemistry from the University of Texas at Arlington. B.S. in Chemistry and Mathematics from St. Lawrence University.
Follow Keith Crandell:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Kristina Burow
Managing Director of ARCH Venture Partners
Kristina Burow is a Managing Director with ARCH Venture Partners. Kristina Burow is focused on the creation and development of biotechnology, pharmaceutical and agbiotechnology companies.
Follow Kristina Burow:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Steven Gillis
Managing Director of ARCH Venture Partners
Steven Gillis is a Managing Director with ARCH, joining the firm as a Venture Partner in 2005. Steven is focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. Steven is a Member of the Board of Directors at Homology Medicines, Inc., Allozyne, Pulmatrix (PULM), Codiak Biosciences, Faraday Pharmaceuticals, Just. Biotherapeutics, VLST, Lodo Therapeutics and Accelerator. Steven serves as Member of the Board of Directors and Chairman of the Board of Directors at VentiRx Pharmaceuticals, Theraclone Sciences, Lycera, VBI Vaccines (VBIV) and PhaseRx. Steven was a Founder and a Member of the Board of Directors at Corixa Corp. and served as Chief Executive Officer from its inception and as its Chairman of the Board of Directors from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Stevens was a Founder and Member of the Board of Directors at Immunex Corp., the most successful venture-funded biotech company in the state of Washington. From 1981 until his departure in 1994, Steven served as Immunex’s Director of Research and Development, Chief Scientific Officer and as Chief Executive Officer of Immunex’s R&D subsidiary. Steven was interim Chief Executive Officer of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a Member of the Board of Directors until 1997. Amgen, Inc. acquired Immunex in 2002. Steven is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. Steven is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Steven received a B.A. degree from Williams College and a Ph.D. from Dartmouth College.
Follow Steven Gillis:
About ARCH Venture Partners, Geisel School of Medicine at Dartmouth, Theraclone Sciences, Tuck School of Business at Dartmouth College: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Clinton Bybee
Co-Founder and Managing Director of ARCH Venture Partners
Clinton Bybee is a co-founder and Managing Director of ARCH Venture Partners. Mr. Bybee concentrates primarily on advanced materials, electronics, semiconductors, photonics, and infrastructure businesses. Mr. Bybee has helped organize and finance numerous companies including MicroOptical Devices (acquired by EMCORE), Cambrios Technologies, Aveso, Innovalight, Intelligent Reasoning Systems (acquired by Photon Dynamics), Semprius, Nanosys, and Xtera Communications. He is a board member of Impinj, Innovalight, Cambrios Technologies, Xtera Communications, Nitronex and Aveso. Mr. Bybee is an organizing member of the Texas Venture Capital Association and currently serves as its first President. Previously, Mr. Bybee worked with ARCH Development Corporation. He also managed a venture investment fund for the State of Illinois and was a production engineer with Amoco Corporation.
Follow Clinton Bybee:
About ARCH Development Corporation, ARCH Venture Partners, Nitronex: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Steven Lazarus
Co-founder and Managing Director, Emeritus Chicago of ARCH Venture Partners
Steven Lazarus is a co-founder and Managing Director, Emeritus of ARCH Venture Partners. He also is a director of the Rand Corporation. Prior to the founding of ARCH Venture Partners, Mr. Lazarus served as CEO of ARCH Development Corporation and as Associate Dean of the Graduate School of Business of the University of Chicago. He previously spent 13 years with Baxter Laboratories in various senior roles, lastly as Group Vice President of the Health Care Services Group of Baxter Travenol Laboratories. Mr. Lazarus also served in Washington D.C. as Deputy Assistant Secretary of Commerce for East-West Trade for the U.S., a government bureau he both founded and directed. Mr. Lazarus is a 21-year veteran of the U.S. Navy, retiring with the rank of Captain in 1973. Mr. Lazarus received an M.B.A. with high distinction from the Harvard Graduate School of Business and holds an A.B. with Honors from Dartmouth College.
Follow Steven Lazarus:
About ARCH Venture Partners, RAND: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Lina Nilsson
Senior Director, Data Science Product of Recursion Pharmaceuticals
Follow Lina Nilsson:
About Recursion Pharmaceuticals: Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Scott Nielsen
Director of Data Engineering of Recursion Pharmaceuticals
Scott wrote his first computer programs as a research assistant studying cosmic rays at the University of Utah and hasn’t stopped. Since then, he has automated the collection of government healthcare sanctions to perform background checks, created an automatic underwriting platform for an insurance company, and helped prevent fraud for an insurance wellness program. He is always eager for opportunities to learn or experience something new, and loves spending time with his wife and four kids.
Follow Scott Nielsen:
About Recursion Pharmaceuticals: Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Jonathan Dry
Director, Early Oncology of AstraZeneca
Jonathan studied Biomedical Sciences at the University of Manchester where his research focused on the genetics of diabetes, exposing him to the richness of information in DNA that can be uncovered with computational tools. He was awarded a scholarship at the University of Exeter to study Bioinformatics, where he collaborated with GlaxoSmithKline to develop computational models determining the risk of recombinant protein breakdown by proteases in host cells. In 2003 Jonathan joined AstraZeneca as the first member of the newly formed Oncology Bioinformatics team. As a scientist and senior scientist he drove adoption of ‘omic data to establish molecular line of sight for new targets, specializing in gene expression microarrays. He introduced a number of pioneering approaches harnessing gene expression data from cancer cell lines to uncover the mechanisms of pathway/drug target dependency, discovering biomarkers of drug response. Throughout his career he has supported and influenced a number of programs, including drugs targeting PARP (Lynparza), mTOR, PI3K, AKT and ERBB. His work for the MEK inhibitor selumetinib led to a transcriptional readout of MEK activity that became the first transcriptomic hypothesis tested in AZ clinical trials. As a team leader and now Director Jonathan has gone on to build a global group focused on harnessing next generation sequencing and genomic data to further AstraZeneca’s oncology drug programs and precision medicine. His team are recognized as leaders in the field, with a number of high profile publications and algorithms now adopted by leading research centers around the world such as the VarDict NGS variant caller. Jonathan carries a strong collaborative attitude and is a champion of open innovation to harness the world’s data and expertise for actionable discovery.
Follow Jonathan Dry:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Bruce Burlington
Non-Executive Director of AstraZeneca
Bruce Burlington is a prominent independent consultant on pharmaceutical product development and regulatory affairs with more than 30 years of experience in regulatory affairs and drug development. Bruce Burlington’s extensive experience in drug and product development comprises several senior posts at Wyeth, including Executive Vice President and Worldwide Head of Regulatory Affairs, where he played a central role in the development and global registration of many products. Prior to joining Wyeth, Bruce Burlington was a leader at the US Food and Drug Administration (FDA) where he served for 17 years in various roles, including director of the Division of Biological Investigational New Drugs, several management positions in the Center for Drug Evaluation and Research, and director of the Center for Devices and Radiological Health. As an infectious disease physician and a leader in regulatory policy, Bruce Burlington has served as the industry representative on the FDA’s Drug Safety and Risk Management Advisory Committee and currently holds Board positions at Cangene Corporation, AstraZeneca, and the International Partnership for Microbicides. Bruce Burlington graduated from Louisiana Tech University with a B.A. in Psychology and Economics and received his M.D. degree from Louisiana State University. He completed his internal medicine internship and residency, as well as his infectious disease fellowship, at the University of Colorado.
Follow Bruce Burlington:
About : AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
David Reif
Associate Director of Cancer Research of AstraZeneca
Dr. Reif serves as an Associate Director of Cancer Research at AstraZeneca. David received his B.S. in Microbiology from the University of Michigan, and his Ph.D. in 1990 in Biochemistry and Molecular Biology from Utah State University in the laboratory of Dr. Steven Aust. He completed his post-doctoral training with Dr. Roy Simmons at Fisons Pharmaceuticals (a predecessor company to AstraZeneca) in Rochester, NY. Dr. Reif then joined the staff at Fisons where he led drug discovery project teams in the areas of Parkinson’s Disease, ALS, and stroke in addition to leading the biochemistry group. In 2000, he was the first to join a new cancer discovery group within AstraZeneca at their facilities in Waltham. Dr. Reif is currently an Associate Director and Operations Manager within the cancer department and works as a member of the cancer management team in managing the portfolio of novel projects for cancer therapy. David is also intimately involved in many community outreach activities. He is a key liaison for AstraZeneca’s involvement with the New England chapter of the American Cancer Society (Making Strides Against Breast Cancer Walk and the Hope Lodge). He currently serves on the Board of Directors of the National Association of Academies of Science as well as the Massachusetts Biotechnology Education Foundation (the last four as Chairman). He also recently ended 10 yrs of service on the Lunenburg School Committee (7 total years as Chairman). Dr. Reif lives in Lunenburg, MA with his wife Trish and their three children (two in college and one in high school).
Follow David Reif:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Jessica Pfennig
Director of Global Digital Governance of AstraZeneca
Jessica Pfennig is Director of Global Digital Governance at AstraZenica and an impactful global leader and digital innovator with over 20 years of strategy and management experience within large pharmaceutical organizations. Jessica has advanced degrees in chemistry, information science and an EMBA. Jessica is in charge of managing and monitoring AZ’s digital asset estate. In this role she influences the future regulations for digital interactions with patients, physicians and payers. She is recognized for integrating risk avoidance and commercial compliance standards to introduce innovative technology and services. Jessica is also the Senior Global Chair for the Digital Innovators within the Healthcare Businesswomen’s Association.
Follow Jessica Pfennig:
About AstraZeneca, AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Mariam Iqbal
Director Of Procurement of AstraZeneca
Follow Mariam Iqbal:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Neerav P. Padliya
Associate Director, Regulatory Affairs of AstraZeneca
Follow Neerav P. Padliya:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Jeremy Berger
Creative Director of Elysium
Follow Jeremy Berger:
About Elysium: Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs.
Neil Poloso
Executive Director, Biological Research of Allergan
Follow Neil Poloso:
About AbbVie, Allergan: Allergan is a global pharmaceutical company.
Tory Brady
Director of Product Engineering of Allergan
Tory Brady’s passion is building software with a keen eye on the customer and the jobs they’re hiring a product to do in their lives. He loves when beautiful design, performant code and comprehensive data intersect. He’s had a fruitful career as a Software Engineer, working for a variety of technology start-ups. Now Tory is applying these learned start-up methodologies to Allergan’s medical aesthetics business as they work to revitalize the digital relationship with their consumers.
Follow Tory Brady:
About Allergan: Allergan is a global pharmaceutical company.
Vijay Raghavan
Senior Director, Management Science of Allergan
Follow Vijay Raghavan:
About Allergan: Allergan is a global pharmaceutical company.
Amy Labroo
Director, Digital Marketing & OmniChannel of GSK
Follow Amy Labroo:
About GSK: GSK Venture Fund is a Massachusetts-based venture capital fund focused on investments within the area of bioelectronics.
Scott Marshall
Managing Director of Precision Analytics of Precision for Medicine
Scott Marshall is the Managing Director, Provide Technology Driven Biomarker Data Integration & Computational Biology at QuartzBio.
Follow Scott Marshall:
About Precision for Medicine, Quartz Bio: Precision for Medicine is a specialized scientific services company helping life science innovators develop medical products.
Lawrence Olanoff
Member of the Board of Directors of Ironwood Pharmaceuticals
Lawrence Olanof is a Special Advisor to the President for Corporate Relations at MUSC. After a long career in the pharmaceutical industry, Lawrence retired from his last position as President and Chief Operating Officer (2006-2010) at Forest Laboratories, Inc., and served as a Member of the Board of Directors at Forest Laboratories, Inc. until 2014. Lawrence is currently a Member of the Board of Directors at Ironwood Pharmaceuticals Inc. and Axovant Sciences Ltd. Lawrence also serves as a Member of the Non-Profit Boards of the Institute for Applied Neurosciences at the Medical University of SC, the Clinical Biotechnology and Research Institute at Roper St. Francis Hospitals and the Horizon Development Project; is a Member of the Advisory Board of BioMotiv and is an ex-officio Member of the MUSC Foundation for Research Development Board. In these affiliations, Lawrence is actively involved in advising companies and non-profit institutions in areas of drug discovery and development. Lawrence was President and Chief Executive Officer of Celsion Corporation from 2005 to 2006. From 1995 until 2005, Lawrencef was responsible for the leadership of research and development activities for Forest Laboratories, Inc., ultimately as its Executive Vice President-Scientific Affairs. From 1993 to 1995, Lawrencef was Senior Vice President-Clinical Research and Development at Sandoz Pharmaceutical Corporation. From 1984 to 1993, Lawrence was employed by The Upjohn Company, where his last position was Corporate Vice President-Clinical Development and Medical Affairs. Lawrence holds M.D. and Ph.D. (Biomedical Engineering) degrees from Case Western Reserve University and was a medical resident and clinical pharmacology fellow at MUSC. Lawrence also holds M.S. degree in Biochemical Engineering from Rutgers University and B.S. degree in Chemical Engineering from Tufts University. Lawrence is the Author or Co-Author of numerous scientific publications in the fields of clinical pharmacology, drug delivery and pharmacokinetics. During his industry career, Lawrence was involved in the approval of some 30 new drugs, new indications or novel formulations in the US.
Follow Lawrence Olanoff:
About : Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Marsha Fanucci
Member of Board of Directors & Audit Committee Chair of Ironwood Pharmaceuticals
Marsha H. Fanucci has been a director since March 2005. Ms. Fanucci served as Senior Vice President and Chief Financial Officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company, from July 2004 through January 2009, where she was responsible for corporate strategy, treasury, financial planning and reporting and operations. While at Millennium since 2000, she also served as Vice President, Finance and Corporate Strategy and Vice President, Corporate Development. (Millennium was acquired by Takeda Pharmaceutical Company Limited in May 2008 and is now Millennium: The Takeda Oncology Company). Ms. Fanucci is a member of the board of directors of Alnylam Pharmaceuticals, Inc. and Ironwood Pharmaceuticals, Inc. She received her B.S. in pharmacy from West Virginia University and her M.B.A. from Northeastern University. Ms. Fanucci’s qualifications to sit on the board include her expertise with public and financial accounting matters, including her experience leading financial organizations in biotechnology companies.
Follow Marsha Fanucci:
About : Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Donovan Pepper
National Director, Local Goverment Relations of Walgreens
Donovan is the National Director of Local Government Relations for Walgreen Co. Prior to this position, Donovan served as the Director of Government Relations for the Illinois Restaurant Association. He has worked for SBC, the Chicagoland Chamber of Commerce, and served on the Appropriations in Political Studies from Univ. of Illinois-Springfield and a Bachelor’s in Political Science from Sangamon State.
Follow Donovan Pepper:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Abey Koshy
Director of Data & Corporate Technologies ,Principal Architect of Walgreens
Abey Koshy is the Director of Data & Corporate Technologies ,Principal Architect at Walgreens.
Follow Abey Koshy:
About Walgreens, Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Kurt Erchinger
Sr. Director, Online Technology, Digital Engineering & Mobile Solutions of Walgreens
Kurt Erchinger is the Sr. Director, Online Technology, Digital Engineering & Mobile Solutions at Walgreens.
Follow Kurt Erchinger:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Kurt Erchinger
Sr. Director, Online Technology, Digital Engineering & Mobile Solutions of Walgreens
Kurt Erchinger is the Sr. Director, Online Technology, Digital Engineering & Mobile Solutions at Walgreens.
Follow Kurt Erchinger:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Jay Lichter
Managing Director of Avalon Ventures
Jay Lichter joined Avalon Ventures as Managing Director in 2007.Dr. Lichter has served on Otonomy’s board of directors since May 2008. Dr. Lichter served as the company’s chief executive officer from inception until November 2010. He is an experienced biotechnology and pharmaceutical business executive with 25 years of experience in management, scientific research and business development. Since 2007, Dr. Lichter has been a managing director at Avalon Ventures, an early stage venture capital fund focused on information technology and life sciences. In that role, he led Avalon’s investments in and served as a director and chief executive officer for privately held biotechnology companies Afraxis, Inc., Carolus Therapeutics, Inc., ReVision Therapeutics, Inc. and Zacharon Pharmaceuticals, Inc. He also currently serves on the board of directors of Aratana Therapeutics, Inc., a public company. Dr. Lichter also led Avalon’s investments in or serves on the board of privately held companies Sova Pharmaceuticals, Inc., Avelas Biosciences, Inc., COI Pharmaceuticals Inc. and Sitari Pharmaceuticals Corp. Dr. Lichter received a doctorate and bachelor’s degree in biochemistry from the University of Illinois. He also completed post-doctoral fellowships at Yale University and Du Pont Merck Pharmaceutical Company.
Follow Jay Lichter:
About Avalon Ventures, Avelas Biosciences, COI Pharmaceuticals, Fortis Therapeutics, Otonomy: Avalon Ventures is an early stage venture capital fund focused on information technology and life sciences.
Jeffrey Gatz
Director of BioIVT
Jeffrey Gatz is the director at BioIVT.
Follow Jeffrey Gatz:
About : BioIVT is a worldwide provider of biological and in vitro products to pharmaceutical and biotechnology organizations
Mark Bakken
Founder, Managing Director of HealthX Ventures
Mark Bakken is the Founder and Managing Partner at HealthX Ventures.
Follow Mark Bakken:
About Creative Destruction Lab (CDL), Cultivation Capital, HealthX Ventures: Madison, WI based venture fund focusing on seed stage investments in digital health companies
David Casey
President, Board of Directors of CVSHealth
David Casey serves as Vice President, Workforce Strategies and Chief Diversity Officer for CVS Health. Casey joined the company in 2010 and is responsible for developing and driving diversity and engagement strategies across the company. He is also focused on ensuring that diversity and inclusion are embedded in CVS Health’s recruitment, talent development, performance management and succession planning efforts. In prior roles, Casey was Chief Diversity Officer at WellPoint, where he led the development and execution of enterprise-wide strategies to leverage diversity management for the workforce, workplace and marketplace. Casey was also a Regional Director of Business Development for Bernard Hodes Group, where he consulted with regional, national and international clients. Casey is a veteran of the United States Marine Corps and served in Operation Desert Storm. Casey has a Bachelor of Science degree in business administration from Indiana Wesleyan University.
Follow David Casey:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Vijay Patel
Senior Director Strategic Partnerships of CVSHealth
Vijay Jun Patel is the Co-Founder & Partner CVS Health Ventures.
Follow Vijay Patel:
About CVSHealth, CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Nels Lindahl
Director, Clinical Decision Systems of CVSHealth
Nels Lindahl is the Director of Clinical Decision Systems at CVS Health.
Follow Nels Lindahl:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Kerry Noone
Director, Employer Branding and Recruitment Marketing of CVSHealth
Kerry Noone is the Director of Employer Branding and Recruitment Marketing at CVS Health.
Follow Kerry Noone:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Michael Goettler
CEO & Executive Director of Viatris
Michael Goettler is the chief executive officer of Viatris and serves on the company’s board of directors. Originally from Germany, Goettler graduated from the Koblenz School of Corporate Management in Germany and then earned an MBA at the University of Texas at Austin. Goettler started his career at Hoechst in Germany, quickly growing to become the executive vice president and CEO of Hoechst Marion Roussel Korea. He joined Pfizer in 2009 as part of the Wyeth acquisition and served in many roles there. Most recently, he was the group president of Pfizer’s Upjohn division and a member of Pfizer’s executive leadership team after previously serving as the global president of Pfizer Inflammation & Immunology; the global president, Rare Disease Business; the senior vice president, global commercial officer, and president of Europe, Specialty Care among other roles. As the CEO of Viatris, Goettler’s responsibilities include executing the company’s strategy and focusing on leveraging the commercial capabilities that Viatris has in China and other key markets. Goettler has extensive experience leading in the global marketplace, having lived and worked in multiple markets in both Asia/Pacific and Europe. He is on the advisory board for Tshingua School of Pharmaceutical Sciences.
Follow Michael Goettler:
About Viatris: Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Rajiv Malik
President & Executive Director of Viatris
Rajiv Malik serves as the president of Viatris and on the company’s board of directors. Originally from India, Malik received a bachelor’s degree and a master’s degree in Pharmaceutical Technology from Punjab University and has 60+ process patents to his credit. Throughout his career, Malik has served in senior leadership roles as head of global regulatory affairs and head of pharma research for Ranbaxy, head of global development and registrations for Sandoz, and CEO of Matrix Laboratories Limited. During his time in this last role, Mylan acquired a controlling stake in Matrix, leading Malik on a path to handle even greater leadership responsibilities at Mylan. Since joining Mylan, Malik held roles including executive vice president, chief operating officer, and head of global technical operations. Malik was integral in developing the strategies for the company’s acquisitions such as Meda , Agila Specialties, and Merck KGaA’s generics business. Importantly, he was also intimately involved in the execution and integration of these and other acquisitions. As the president of Viatris, Rajiv’s responsibilities include overseeing day to day operations, commercial development, medical, IT, quality functions, R&D and the company’s commercial business units. He is especially suited for these varied roles given his unique leadership profile combining a global perspective on healthcare challenges as well as vast experience in scientific, commercial, and financial operations.
Follow Rajiv Malik:
About Viatris: Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Azim Munivar
Medical Director of Biohaven Pharmaceutical
Azim Munivar is the Medical Director at Biohaven Pharmaceutical.
Follow Azim Munivar:
About Biohaven Pharmaceutical: Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
Jared Casner
Director, Engineering of Pear Therapeutics
Follow Jared Casner:
About Pear Therapeutics: Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Joseph Authement
US Director Strategic Accounts-Robotics and Digital Solutions of Johnson & Johnson
Follow Joseph Authement:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Alice Lin Fabiano
Global Director of Social Innovation & Investment, Global Community Impact of Johnson & Johnson
Alice Lin Fabiano is a Global Director at Johnson & Johnson, Global Community Impact. In this capacity, she leads its social innovation strategy and investments in the discovery, engagement, and celebration of purpose driven entrepreneurs, with a focus in health technology and impact investing.
Follow Alice Lin Fabiano:
About Johnson & Johnson, Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Daniel Watts
Director, Global Process Owner, Global Contracting Solutions of Johnson & Johnson
Follow Daniel Watts:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Hari Kamaraju
Director and Head of Manufacturing Excellence, Advanced Therapies of Johnson & Johnson
Follow Hari Kamaraju:
About Janssen Belgium, Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Bret Evans
Sr Director IT of Johnson & Johnson
Currently Bret is the Sr. Director of IT Supply Chain for Johnson & Johnson Ethicon & CSS business.
Follow Bret Evans:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Rick Desmarais
Director Global JJOS Deployment Leader of Johnson & Johnson
Follow Rick Desmarais:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Joy Marini
Director of Corporate Contributions of Johnson & Johnson
Joy Marini became Director of Corporate Contributions in 2007, following 6 years with the Johnson & Johnson Pediatric Institute. Joy is responsible for Johnson & Johnson’s international programs on maternal and infant health, gender-based violence and gender inequality, and economic empowerment of women. She has been instrumental in developing sustainable partnership initiatives, most notably for her efforts on a Neonatal Resuscitation Program (NRP) in China — a 5-year collaboration between the Chinese Ministry of Health, the American Academy of Pediatrics (AAP), several Chinese health-professional organizations, and Johnson & Johnson, which reduced neonatal mortality by 54% in over 300 measured hospitals. Joy has contributed to the development of publications for parents and health professionals, including the Compendium of Postpartum Care with the Association of Women’s Health, Obstetrics and Neonatal Nursing, and Eating Behaviors of the Young Child with the AAP. Joy earned her MS Physician Assistant from the University of Medicine and Dentistry of New Jersey in 1997. She received an MBA from Rider University.
Follow Joy Marini:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Ravi Bhatia
Scientific Director of Johnson & Johnson
Follow Ravi Bhatia:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Reggie Fortson
Director of Product Lifecycle Management (PLM) of Johnson & Johnson
Follow Reggie Fortson:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Susan Can
Senior Director & Global Corporate Brand and Corporate Affairs of Johnson & Johnson
Follow Susan Can:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Susan Can
Senior Director & Global Corporate Brand and Corporate Affairs of Johnson & Johnson
Follow Susan Can:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Gregory Smith
IT Director, I&AM Engineering of Johnson & Johnson
Follow Gregory Smith:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Ilya Shestopalov
Director of Bluebird Bio
Follow Ilya Shestopalov:
About Bluebird Bio, Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Sharad Mansukani
Member of the Board of Directors of IMS Health
Sharad Mansukani has served as a Director of IMS Health since April 2010. Sharad has served as a TPG Senior Advisor since 2005. He serves on the board of directors of Surgical Care Affiliates, Inc., IASIS Healthcare Corp., Immucor Inc. and Par Pharmaceuticals Companies, Inc. Sharad serves as Strategic Advisor to the board of directors of CIGNA and previously served as Vice Chairman of HealthSpring Inc. Sharad also serves on the board of directors of the Children’s Hospital of Philadelphia and on the editorial boards of the American Journal of Medical Quality, Managed Care, Biotechnology Healthcare and American Health & Drug Benefits. Sharad was senior vice president and chief medical officer at Health Partners, a 150,000 member Medicaid and Medicare health plan owned by the Philadelphia-area medical schools. Sharad was appointed to Medicare’s Payment Advisory and Oversight Committee, and he was previously Senior Advisor to CMS and a member of the Medicare Reform Executive Committee. Sharad previously served on the faculty at the University of Pennsylvania and at Temple University School of Medicine. Sharad completed his residency and fellowship in ophthalmology at the University of Pennsylvania School of Medicine and a fellowship in quality management and managed care at the Wharton School of the University of Pennsylvania.
Follow Sharad Mansukani:
About : IMS Health provides information, services and technology for the pharmaceutical and healthcare industry.
Karen Katen
Member of the Board of Directors of IMS Health
Karen Katen has served as a Director of IMS Health since March 2015. Karen Katen began her career at Pfizer in 1974 and held a series of management positions with increasing responsibility, including President of Pfizer Global Pharmaceuticals and Executive Vice President of Pfizer Inc. from 2001 to 2005 and President of Pfizer Human Health from 2005 to 2007. She retired in 2007 as Vice Chairman of Pfizer Inc. Recently, she also served as Chairman of the Pfizer Foundation, a charitable foundation affiliated with Pfizer. She serves on the boards of directors of Air Liquide, Catamaran Corporation, Harris Corporation and The Home Depot. Karen also chairs the RAND Health Board of Advisors and is a member of the Takeda Global Advisory Board and the Novo Nordisk Advisory Committee. She also serves as a Senior Advisor to Essex Woodlands, a growth equity healthcare investment company. Karen holds B.A. and M.B.A. degrees from the University of Chicago, where she is a Trustee of the university and a council member of the Booth School of Business.
Follow Karen Katen:
About : IMS Health provides information, services and technology for the pharmaceutical and healthcare industry.
Ronald Rittenmeyer
Member of the Board of Directors of IMS Health
Follow Ronald Rittenmeyer:
About American International Group, IQVIA, Tenet Healthcare Corporation: IMS Health provides information, services and technology for the pharmaceutical and healthcare industry.
Jiahao Qiu
Member of the Board of Directors of Jaguar Health
Jiahao Qiu has served as a member of our board of directors since February 2014. Since 2010, . Qiu has served as a Principal of BioVeda China Fund, a life science investment firm. From 2009 to 2010, he served as an interpreter for the Delegation of the European Union to China. Qiu holds a B.S. in Biotechnology from the Jiao Tong University in Shanghai, China. We believe Qiu is qualified to serve on our board of directors due to his experience with evaluating, managing and investing in life science portfolio companies for BioVeda China Fund.
Follow Jiahao Qiu:
About : Jaguar Health brings naturally derived important health solutions to all animals of the world, as proprietary.
Melvin Yellin
Managing Director of Acreage Holdings
Melvin Yellin is a Founder of Acreage Holdings, a vertically integrated cannabis company licensed in 12 states. He is also currently a director of USA Inc., having previously been a partner at Tandem Global Partners, which was a globally focused money manager that offered investment services to sophisticated institutions and individuals, focusing primarily on alternative investment strategies. Prior to joining Tandem. Mr. Yellin spent the bulk of his career at Bankers Trust Company and was a Partner, Executive Vice President and General Counsel when it merged with Deutsche Bank. He had global responsibility for over 350 professionals and served on the Bank’s Risk Committee, New Business Committee and its Investment Banking Management Committee, which included the significant Venture Capital business. Mr. Yellin was a member of the Symbol Technologies, Inc. (NYSE) Board of Directors (Audit, Compensation and Governance Committees) as well as a director of numerous privately held companies and not-for-profits. Symbol was the world’s premier developer of bar code and RFID software and hardware. Symbol was later successfully sold to Motorola. During his career, Mr. Yellin has acted as chairman, speaker and author for numerous business organization programs including those run by the Conference Board, the NACD, Columbia Business School (ODX) and the Wisconsin School of Business. Mr. Yellin served as the President of the New York Chapter of the National Association of Corporate Directors and a member of the New York Clearing House GC Committee. He was selected for “Who’s Who in American Law,” The International “Who’s Who of Contemporary Achievement” and the “International Directory of Distinguished Leadership”.
Follow Melvin Yellin:
About Acreage Holdings: Acreage Holdings is a vertically integrated, multi-state owner of cannabis licenses and assets in states.
Joe Echevarria
Board of Directors of Pfizer
Chief Executive Officer of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. During his 36-year tenure with Deloitte, he served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner and U.S. Managing Partner and Chief Operating Officer. Director of The Bank of New York Mellon Corporation. Member of the President’s Export Council and the Presidential Commission on Election Administration. Chair of President Obama’s My Brother’s Keeper Alliance. Member of the Board of Trustees of the University of Miami. Our Director since 2015. Member of our Audit, Regulatory and Compliance and Science and Technology Committees.
Follow Joe Echevarria:
About : Pfizer provides access to safe and effective and affordable medicines and health care services.
Brian Coleman
Director – Digital Forensics & Insider Threat of Pfizer
Follow Brian Coleman:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
James Harnett
Senior Director, Real World Data & Analytics of Pfizer
Dr. James Harnett is a Senior Director in Real World Data and Analytics (RWDnA) for Pfizer’s Patient Health & Impact organization. Dr. Harnett has worked at Pfizer for over 15 years and supported establishing the RWDnA function. He was previously Team Lead in Outcomes Research and a Market Access Lead. He has conducted research across numerous therapeutic areas, currently focusing on oncology, vaccines, and inflammation & immunology, authoring over 30 peer-reviewed publications. Dr. Harnett has received awards for innovation on external partnerships and advanced analytics and use of real world evidence for regulatory decision making. He has a Doctor of Pharmacy degree and Master of Science degree in Clinical Epidemiology and Health Services Research.
Follow James Harnett:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Margi McLoughlin
Executive Director of Pfizer
Margi McLoughlin, PHD is Executive Director, WWBD and Partner at Pfizer Ventures. Margi invests in companies working in areas aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in 4D Molecular Therapeutics, Adapsyn, BioAtla, Cortexyme and System1. Through these investments, she works with the companies to help advance products and technologies of value to the pharmaceutical industry. Margi began her career at Mallinckrodt Medical, holding positions in Discovery Research, followed by Technology Planning. In 1999, she moved to Yale University where she worked as Associate Director in the Office of Cooperative Research. Since joining Pfizer Worldwide Business Development in 2001, she has had roles of increasing responsibility and led transactions with multiple biotech companies, including Ablexis, Gliknik and Excaliard. In addition, Margi played a significant role in defining Pfizer’s Centers for Therapeutic Innovation business model.
Follow Margi McLoughlin:
About Pfizer, Pfizer Venture Investments: Pfizer provides access to safe and effective and affordable medicines and health care services.
Donna Armentano
Executive Director External R&D Innovation and Global Head Gene Therapy of Pfizer
Follow Donna Armentano:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Yael Gozin
Senior Director, Global Clininal Submissions Quality of Pfizer
Yael Gozin is a senior director at Pfizer, where she works with clinical development teams across Pfizer’s portfolio, which raised her interests in the use of technology to improve the processes and data quality associated with clinical development and regulatory submissions. Yael provides technical guidance both in designing and implementing innovative AI solutions to automate quality processes and coaching and mentoring of project teams across different therapeutic areas including oncology, innovative pharma, established products, and consumer products. She holds a doctorate from Swiss Federal Institute of Technology, Zurich (ETH Zurich) in organic chemistry and a master’s degree from the Weizmann Institute in organometallic chemistry.
Follow Yael Gozin:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Gerald Fetterly
Senior Director, Clinical Pharmacology of Pfizer
Dr. Gerald J. Fetterly is an Associate Professor of Oncology and the Director of the Pharmacokinetics and Pharmacodynamics Core Resource in the Department of Medicine at Roswell Park Cancer Institute. He is a clinical pharmacologist/pharmacokineticist who received his doctoral degree in Pharmaceutical Sciences from the University at Buffalo in 2000, where he has also been an Adjunct Assistant Professor since 2008. He possesses considerable expertise in developing oncology agents and the liposomal encapsulation of drugs. Specifically, his doctoral work and subsequent publications focused on an extensive assay development and comparison of the PK/PD relationships of various anticancer drugs, such as liposomal paclitaxel, trabectedin, and mTOR inhibitors. He has developed both preclinical and clinical PK/PD models to characterize the temporal relationship between the PK of the drug in relation to the time course of neutropenia and transaminase elevation. Prior to joining Roswell Park Cancer Institute, he worked at Cognigen to further his expertise in population PK/PD modeling to provide consulting services for both industry and academia to assess the impact of patient factors that are sources of variability in not only pharmacokinetics but also the PK/PD relationships for both efficacy and safety, mainly for oncology and neuropharmacology drugs. At Cognigen, he led and managed interdepartmental projects in Clinical Pharmacology, provided sparse sampling designs for clinical pharmacology trials, provided clinical pharmacology services for regulatory strategy during Advisory Board and Sponsor/FDA meetings, reviewed the non-clinical as well as clinical pharmacology development sections of various INDs and NDAs, as well as assisted in the interpretation of preclinical data and extrapolation of implications for human clinical development utilizing PK/PD modeling approaches. From 2000-2002, he was a clinical pharmacology and biopharmaceutics reviewer at the FDA. The experience of working with the agency has allowed him to supply insight to industry about the necessary components for a successful IND and NDA submission, along with guiding dose selection during the drug development process.
Follow Gerald Fetterly:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Jay Bergeron
Director of Pfizer
Jay Bergeron is Director, Translational and Bioinformatics, at Pfizer and responsible for informatics support for Clinical Research and Precision Medicine.
Follow Jay Bergeron:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Brian Higgins
Director, Architecture, Platform Engineering & Support Lead of Pfizer
Follow Brian Higgins:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Stephen Kagan
Senior Director, Global Medical Affairs, Rare Disease of Pfizer
Follow Stephen Kagan:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Andrea Mancuso
Director, Training and Education Lead of Pfizer
Follow Andrea Mancuso:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
James Tornos
Senior Director Global Procurement of Pfizer
Follow James Tornos:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Julia Brosnan
Director, External Collaborations and Scientific Alliances of Pfizer
Follow Julia Brosnan:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Steve Hammond
Director Process Analytical Support of Pfizer
Follow Steve Hammond:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
George Bashirians
Director, Diagnostics Lead of Pfizer
Follow George Bashirians:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Cal Austin
Director – Idea Sprint Lab of Pfizer
Follow Cal Austin:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Kelly Zou
Senior Director & Analytic Science Lead of Pfizer
Follow Kelly Zou:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Arpita Maiti
Executive Director & Global Head, Emerging Science & Innovation Lead – Inflammation & Immunology of Pfizer
Follow Arpita Maiti:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Firelli Alonso
Senior Director, External Supply of Pfizer
Follow Firelli Alonso:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Jane Wiltshire
Senior Director, Business Technology – Collaboration Center of Excellence of Pfizer
Follow Jane Wiltshire:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Jane Wiltshire
Senior Director, Business Technology – Collaboration Center of Excellence of Pfizer
Follow Jane Wiltshire:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Charles Kunsch
Sr. Director, AbbVie Ventures of AbbVie
Follow Charles Kunsch:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Daniel Gandor
Director, US Customer Experience, and Oncology & Specialty of AbbVie
Follow Daniel Gandor:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Jeremy Edmunds
Executive Director Immunology Chemistry of AbbVie
Follow Jeremy Edmunds:
About AbbVie, AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Chen Wang
Director of Purification Development, Process Sciences of AbbVie
Follow Chen Wang:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Diana Guarin
Associated Director Regulatory Affairs of AbbVie
Diana Guarin is the Regualtory Affairs Director at AbbVie.
Follow Diana Guarin:
About AbbVie, AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Vangelis Vergetis
Co-Founder & Executive Director of Intelligencia
Vangelis is working on the intersection of data science, technology, and healthcare. In 2017 he co-founded Intelligencia, a company that uses AI to assess and minimize the risk of drug development. Prior to that he was a management consultant for more than 12 years – at both McKinsey and Hakluyt – advising healthcare clients and investors on a variety of topics, including digital technologies, clinical development and early commercialization. Outside of Intelligencia, Vangelis is a board member and member of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare (AAIH), serves on the Dean’s Advisory Council for Cornell’s faculty of Computing & Information Science (CIS), and is an advisor and investor in technology companies in both the US and Europe. He holds a BS and PhD in Computer Science and Electrical Engineering.
Follow Vangelis Vergetis:
About Intelligencia: Intelligencia is a SaaS company that applies machine learning to assess and mitigate the risk in clinical development strategy/design.
Dimitrios Skaltsas
Co-Founder, Executive Director of Intelligencia
Dimitrios has led McKinsey’s team for big data & AI applications in R&D for life sciences, and has built SaaS products focusing on clinical development. He serves as an advisor, and has also invested, in several technology companies with a focus on big data. He holds an MBA from INSEAD, where he is also currently an Executive in Residence for AI/ Digital.
Follow Dimitrios Skaltsas:
About INSEAD, Intelligencia: Intelligencia is a SaaS company that applies machine learning to assess and mitigate the risk in clinical development strategy/design.
Amir Zur
Sr. Director, Head of Products of Digital Health of Teva Pharmaceutical Industries
Amir Zur is a Sr. Director, Head of Products of Digital Health in Teva Pharmaceuticals, Mr. Zur leads the digital products roadmap, development life-cycle and quality to build Drug-Device Combination and Medical Device products to improve outcomes and treatments to patients. Previously at Teva, he led the teams who built a novel innovative product from scratch and established digital foundations, processes and transformation in the company. The product was recently approved by the FDA as the first of its kind in respiratory and in the entire Health industry. During his career Amir held vast leadership roles as an executive manager for more than 20 years in the digital industry both global large and small companies.
Follow Amir Zur:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Paul Clark
Member of the Board of Directors of Catalent Pharma Solutions
Paul Clark is an Operating Partner and Strategic Advisory Board member of Genstar Capital LLC. He is responsible for expanding Genstar’s life sciences practice. Paul was Director, CEO and President of ICOS Corporation from 1999 until the sale to Eli Lilly and Company in 2007. He also served as Chairman from 2000 until 2007. ICOS was a top ten biotechnology company. Clark led the transition to a commercial organization achieving profitability while developing Cialis into a $ 1 billion product which became the market leader surpassing Viagra in many countries. Paul has over 30 years of experience in the pharmaceutical and biotechnology industry. From 1984 to 1998, he worked in various capacities for Abbott Laboratories, a health care products manufacturer, retiring from Abbott Laboratories as Executive Vice President and Board member. In addition to other responsibilities during this time he ran the pharmaceutical business for fourteen years. Clark also held senior positions with Marion Laboratories, a pharmaceutical company, and Sandoz Pharmaceuticals (now Novartis). Paul is a member of the board of Directors of Agilent Technologies, Catalent Pharma Solutions, Harlan Labs and Cerevast Therapeutics. Clark received his MBA from Dartmouth College, Amos Tuck School. His BS in Finance from the University of Alabama.
Follow Paul Clark:
About : Catalent provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies.
Donald Morel
Member of the Board of Directors of Catalent Pharma Solutions
Donald Morel has been a board member since November 2015. Morel retired in June 2015 as Chairman of West Pharmaceutical Services, Inc., a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, a position he had held since March 2003. He also served as West’s Chief Executive Officer from April 2002 until April 2015 and as its President from April 2002 until June 2005. Currently, Morel serves as Chairman of the Board of Directors of the American Oncologic Hospital of the Fox Chase Cancer Center. He also serves as Chairman of the Board of Trustees of the Franklin Institute and is a Trustee of Lafayette College. Additionally, Morel has been a Director of Integra Life Sciences Holdings Corporation since August 2013. Prior to that, he served as a Director of Kensey Nash Corporation from 2010 until 2012. Morel obtained a Master of Science degree and a Ph.D. in Materials Science from Cornell University and a Bachelor of Science degree in Engineering from Lafayette College.
Follow Donald Morel:
About : Catalent provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies.
Donald Morel
Member of the Board of Directors of Catalent Pharma Solutions
Donald Morel has been a board member since November 2015. Morel retired in June 2015 as Chairman of West Pharmaceutical Services, Inc., a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, a position he had held since March 2003. He also served as West’s Chief Executive Officer from April 2002 until April 2015 and as its President from April 2002 until June 2005. Currently, Morel serves as Chairman of the Board of Directors of the American Oncologic Hospital of the Fox Chase Cancer Center. He also serves as Chairman of the Board of Trustees of the Franklin Institute and is a Trustee of Lafayette College. Additionally, Morel has been a Director of Integra Life Sciences Holdings Corporation since August 2013. Prior to that, he served as a Director of Kensey Nash Corporation from 2010 until 2012. Morel obtained a Master of Science degree and a Ph.D. in Materials Science from Cornell University and a Bachelor of Science degree in Engineering from Lafayette College.
Follow Donald Morel:
About : Catalent provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies.
Richard Sackler
Director Purdue Pharma of Purdue Pharma
Richard Sackler is Member of Scientific Advisory Board at Kolltan Pharmaceuticals. Richard S. Sackler, Ph.D., M.D. served as the President of Purdue Pharma L.P. (Formerly, Purdue Frederick). Sackler serves as Co-chairman of Purdue Pharma.Sackler serves as a Member of Scientific Advisory Board at Kolltan Pharmaceuticals, Inc. Sackler serves as a Member of Scientific Advisory Board at Verastem, Inc. Sackler is an Adjunct Professor of Genetics at Rockefeller University.
Follow Richard Sackler:
About Purdue Pharma: Purdue Pharma L.P., a pharmaceutical company committed to improving patients’ lives and serving the healthcare community.
Charles P. McKenney
Board of Directors of Arrowhead Pharmaceuticals
Charles P. McKenney has maintained a government affairs law practice in Pasadena, California since 1989, representing businesses and organizations in their relations with government regarding their obligations under state and local land use and trade practices laws. From 1973 through 1989, he served as Attorney for Corporate Government Affairs for Sears, Roebuck and Co., helping organize and carry out Sears’ Western state and local government relations programs. Mr. McKenney has served two terms on the Pasadena, California City council, on several city boards and committees in Pasadena, including three city Charter Reform Task Forces.
Follow Charles P. McKenney:
About : Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Edward W. Frykman
Board of Directors of Arrowhead Pharmaceuticals
Edward W. Frykman has been an Account Executive with Crowell, Weedon & Co. since 1992. Previously, Mr. Frykman served as Senior Vice President of L.H. Friend & Co. Both Crowell, Weedon & Co. and L.H. Friend & Co. are investment brokerage firms located in Southern California. In addition, Mr. Frykman was a Senior Account Executive with Shearson Lehman Hutton where he served as the Manager of the Los Angeles Regional Retail Office of E. F. Hutton & Co.
Follow Edward W. Frykman:
About : Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Ashley Witmer
Associate Director, Bioreactor Scale-up and Development of Regeneron
Follow Ashley Witmer:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Andrea Hooper
Director of Regeneron
Follow Andrea Hooper:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Derek Fetzer
Director and Customer Insights & Market Access of Regeneron
Follow Derek Fetzer:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Amy Johnson
Associate Director of Regeneron
Follow Amy Johnson:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Serge Monpoeho
Sr Director of Regeneron
Follow Serge Monpoeho:
About Regeneron, Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Kristian Link
Associate Director, Analytical Development of Moderna Therapeutics
Follow Kristian Link:
About Moderna Therapeutics: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Paul Mitchell
Member of the Board of Directors of Alkermes
Paul Mitchell has been a director of Alkermes since April 2003. He served as the Chief Financial Officer and Treasurer of Kenet, Inc. from 2002 until 2009. Prior to joining Kenet, Paul Mitchell was the Chief Financial Officer and Treasurer of Kopin Corporation from April 1985 through September 1998. From September 1998 through June 2001, Paul Mitchell served in a consulting role at Kopin as Director of Strategic Planning. Prior to joining Kopin,Paul Mitchell worked for the international accounting firm of Touche Ross & Co. from 1975 to 1984. Paul Mitchell is also President of Mitchell Financial Group and a member of the Board of Directors of several private companies. He is a director of the Marblehead Youth Basketball Association. Paul Mitchell is a graduate of College of the Holy Cross (B.A. Economics) and Northeastern University (M.S. Accounting) and he is also a Certified Public Accountant.
Follow Paul Mitchell:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Aenor Sawyer
Director, University of California, Space Health; Dir. Skeletal Health Service of University of California, San Francisco
Aenor Sawyer is an Orthopaedic Surgeon at UCSF and Associate Director of Digital Health in Biomedical Informatics at the Clinical & Translational Science Institute where she co-directs the UCSF T1 Catalyst Digital Health Grants program. Aenor Sawyer is also co-Founder of Trinity, a web-based collaboration technology for Virtual Tumor Board and Multidisciplinary Management of complex patients.
Follow Aenor Sawyer:
About Translational Research Institute for Space Health (TRISH), Trinity Labs, University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Sanchita Bhattacharya
Scientific Program Director of University of California, San Francisco
Sanchita Bhattacharya is the Bioinformatics Project Lead at UCSF School of Medicine.
Follow Sanchita Bhattacharya:
About UCSF School of Medicine, University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Daniel Lowenstein
Director, Physician-Scientist Education & Training of University of California, San Francisco
Daniel Lowenstein is the Director, Physician-Scientist Education & Training at UCSF.
Follow Daniel Lowenstein:
About University of California, San Francisco, University of California, San Francisco, University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Mark Savage
Director, Health Policy of University of California, San Francisco
Mark is Director of Health Policy at UC San Francisco’s Center for Digital Health Innovation, where he leads health policy strategy and development and data governance for the Center and its projects to advance interoperability, electronic health information exchange and access for patients, providers and consumers. Until April, Mark was Director of Health IT Policy and Programs at the National Partnership for Women & Families. There, he oversaw the National Partnership’s strategy and work to advance electronic health information access and exchange as the backbone for patient access and engagement, delivery reform and shared care planning, patient-generated health data and social determinants of health, and health equity. The work included policy development throughout delivery system reform (MACRA, 21st Century Cures), the Meaningful Use program, and other national programs such as the Interoperability Roadmap. His team also convened the Consumer Partnership for eHealth, a coalition of more than 50 leading consumer, patient and labor organizations working to advance patient-centered health IT.
Follow Mark Savage:
About University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
